Artis BioSolutions expands genetic-medicine manufacturing with Bilbao center

Artis BioSolutions announced on August 26, 2026, the launch of a Genetic Medicines Center of Excellence in Bilbao, Spain.

The facility combines enzymatic synthetic DNA manufacturing with mRNA drug-substance production, lipid nanoparticle (LNP) formulation and manufacturing, and GMP drug-product manufacturing.

The center is designed to provide an end-to-end development and manufacturing pathway—from genetic-material starting materials through clinical supply and commercialization—while reducing technology-transfer burdens for customers.

Located in the Zamudio Technology Park in Spain’s Basque Country, the site spans about 37,000 square feet and includes four cGMP processing suites, a fill-finish suite, eight preclinical/research laboratories, and gram-scale DNA production capacity.

The Bilbao operation complements Artis’s Boston BioSolutions facility in Watertown, Massachusetts, expanding its U.S.–European manufacturing footprint.

The company did not disclose the investment amount or expected employment associated with the Spanish expansion.